Compare Eastern Bankshares Inc. Common Stock (EBC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eastern Bankshares Inc. Common Stock vs Incyte Corporation — how do they compare? Eastern Bankshares Inc. Common Stock trades at $20.77 (market cap $4.76B), while Incyte Corporation trades at $111.75 (market cap $22.63B). The key difference: Incyte Corporation is far larger — about 4.8× Eastern Bankshares Inc. Common Stock's market cap, and Eastern Bankshares Inc. Common Stock pays a 2.69% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eastern Bankshares Inc. Common Stock for 0 Days and Incyte Corporation for 33 Days on average.
| EBC | INCY | |
|---|---|---|
Market Cap | $4.76B | $22.63B |
Volume | 2,941,879 | 1,869,988 |
Sector | Financials | Health |
52-Week High | $23.65 | $129.93 |
52-Week Low | $16.73 | $86.17 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $4.98B | $18.13B |
Dividend Yield | 2.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eastern Bankshares (EBC) trades at $20.96, down 0.85% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.71, net income margin of 33.47%, and recent Q2 2026 EPS beat. Analyst consensus is bullish with a $25.60 price target. Recent news highlights institutional buying and upcoming Q3 2026 earnings.
The outlook is positive given solid profitability, attractive valuation, and analyst support. Key risks include integration challenges from recent acquisitions and interest rate sensitivity. Upside potential exists if earnings momentum continues, but investors should monitor net cash flow trends and competitive pressures.
Incyte (INCY) trades at $108.62, down 2.46% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 13.84, robust profitability margins, and a significant earnings beat in Q2 2026. Recent news highlights FDA approval for Atebrioz and a strategic push for post-JAKAFI growth targeting $4B in sales. Operating cash flow surged to $1.41B in 2025, supporting financial health.
The outlook is mixed: analyst consensus is bullish with a $133.14 price target, but near-term technical pressure and Q3 2026's expected EPS loss pose risks. Long-term growth depends on pipeline execution and diversification beyond JAKAFI, with competitive and regulatory challenges as key investor considerations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eastern Bankshares Inc. Common Stock
Eastern Bankshares, Inc. is the holding company for Eastern Bank, a Massachusetts-based bank operating more than 125 branches across eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island, offering consumer and business banking along with wealth management through its Cambridge Trust divisions.
Read more on EBC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
